There are currently 548 clinical trials in Charlotte, North Carolina looking for participants to engage in research studies. Trials are conducted at various facilities, including Carolinas Medical Center, Carolinas Medical Center/Levine Cancer Institute, Novant Health Presbyterain Medical Center and Levine Cancer Institute. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Treating Respiratory Emergencies in Children Study
Recruiting
Over 200,000 children have a 911 Emergency Medical Services (EMS) activation for respiratory distress each year, most of whom have acute wheezing. Early treatment in the prehospital setting could more rapidly relieve respiratory distress symptoms, prevent hypoxia, reduce invasive interventions, and reduce the need to be hospitalized, thereby facilitating earlier return to normal daily activities. Preliminary data from one site found hospital admission was reduced from 30% to 21% among children w... Read More
Gender:
All
Ages:
Between 2 years and 17 years
Trial Updated:
02/22/2024
Locations: Mecklenburg County EMS, Charlotte, North Carolina
Conditions: Asthma in Children
A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer
Recruiting
This is a randomized controlled trial to compare survival for patients who undergi robotic assisted laparoscopy versus open radical hysterectomy and lymph node assessment for the treatment of early stage cervical cancer.
Gender:
Female
Ages:
18 years and above
Trial Updated:
02/21/2024
Locations: Novant Health Cancer Institute, Charlotte, North Carolina
Conditions: Cervical Cancer
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Recruiting
Tagraxofusp is a protein-drug conjugate consisting of a diphtheria toxin redirected to target CD123 has been approved for treatment in pediatric and adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). This trial aims to examine the safety of this novel agent in pediatric patients with relapsed/refractory hematologic malignancies. The mechanism by which tagraxofusp kills cells is distinct from that of conventional chemotherapy. Tagraxofusp directly targets CD123 that is pre... Read More
Gender:
All
Ages:
Between 1 year and 21 years
Trial Updated:
02/20/2024
Locations: Carolina-Levine Children's Hospital, Charlotte, North Carolina
Conditions: Hematologic Malignancy, AML, ALL, BPDCN, MDS, Lymphoblastic Lymphoma, Lymphoma, B-Cell, Lymphoma, T-Cell, Hodgkin Lymphoma, Mixed Phenotype Acute Leukemia, Acute Undifferentiated Leukemia
A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma
Recruiting
This study will be conducted in 2 parts. The first part is a phase 1 single-agent dose escalation,optimization, and expansion study of tegavivint in patients with advanced HCC after failure of at least one line of prior systemic therapy. In the second part of the study, the combination of tegavivint plus pembrolizumab will be assessed with a limited dose escalation followed by a randomized dose optimization.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/20/2024
Locations: Levine Cancer Institute, Charlotte, North Carolina
Conditions: Advanced Hepatocellular Carcinoma
Evolutionary Therapy for Rhabdomyosarcoma
Recruiting
This clinical trial will evaluate 4 different strategies of chemotherapy schedules in newly diagnosed participants with metastatic Fusion Positive (alveolar) Rhabdomyosarcoma. The participant and their physician will choose from: Arm A) a first strike therapy, Arm B) a first strike-second strike (maintenance) therapy, Arm C) an adaptively timed therapy, and Arm D) conventional chemotherapy.
Gender:
All
Ages:
All
Trial Updated:
02/20/2024
Locations: Carolinas Medical Center, Levine Cancer Institute, Charlotte, North Carolina
Conditions: Rhabdomyosarcoma
CIED Infection Quality Initiative Demonstration Project
Recruiting
The aim of this Quality Initiative (QI) demonstration project is to develop a model to increase guideline-driven care for patients with cardiovascular implantable electronic devices (CIED) infection. Multidisciplinary teams will be established to carry out the multifaceted intervention. This program seeks to improve early identification and diagnosis, appropriate treatment, and faster time to treatment of CIED infection.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/19/2024
Locations: Atrium Health, Charlotte, North Carolina
Conditions: Infections
Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction
Recruiting
Heart failure with preserved ejection fraction (HFPEF) is common and deadly but without therapy. Inconclusive studies such as TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) suggest spironolactone may be effective in HFPEF, but it is generic and will not be studied by industry. SPIRRIT is a unique Registry-Randomized Clinical Trial (RRCT) that will test the hypothesis that spironolactone plus standard of care compared to standard of care alone reduc... Read More
Gender:
All
Ages:
Between 50 years and 99 years
Trial Updated:
02/15/2024
Locations: Mid Carolina Cardiology Research, Charlotte, North Carolina
Conditions: Heart Failure With Preserved Ejection Fraction
Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors
Recruiting
This is a multi-cohort single arm phase II/screening trial of the combination of a fusion protein that binds EphrinB2 and blocks interaction with cell surface EphB receptors (sEphB4-HSA) in combination with an anti-PD1 antibody (MK-7435 / Pembrolizumab) for treatment of patients with specific solid tumors. There will be four cohorts in this trial: Cohort A, phase II 2nd line trial of sEphB4-HSA and pembrolizumab for platinum refractory metastatic urothelial carcinoma. Cohort B, phase II 3rd lin... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/14/2024
Locations: Levine Cancer Institute-Carolinas Medical Center, Charlotte, North Carolina
Conditions: Stage IV Bladder Urothelial Carcinoma, Prostate Cancer, Urothelial Carcinoma
A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
Recruiting
This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
02/14/2024
Locations: American Health Research, Inc., Charlotte, North Carolina
Conditions: Refractory Chronic Cough
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough (CALM-2)
Recruiting
This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
02/14/2024
Locations: PMG Research of Charlotte, LLC, Charlotte, North Carolina
Conditions: Refractory Chronic Cough
Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry
Recruiting
Continuation of the CARRA Registry as described in the protocol will support data collection on patients with pediatric-onset rheumatic diseases. The CARRA Registry will form the basis for future CARRA studies. In particular, this observational registry will be used to answer pressing questions about therapeutics used to treat pediatric rheumatic diseases, including safety questions.
Gender:
All
Ages:
21 years and below
Trial Updated:
02/13/2024
Locations: Levine Children's Hospital / Carolinas Medical Center, Charlotte, North Carolina
Conditions: Rheumatic Joint Disease
A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss
Recruiting
The purpose of the study is to see if Clascoterone can help people with male pattern hair loss to recovery and see if the treatment is effective and safe and how well the drug is tolerated by subjects. Within this study, the Clascoterone solution will be compared to a placebo. The study has 2 parts: Part 1 will see if Clascoterone solution is effective and safe compared to a placebo when applied twice daily for up to 6 months. Part 2 will see the long-term safety and efficacy of the Clascote... Read More
Gender:
Male
Ages:
18 years and above
Trial Updated:
02/09/2024
Locations: On Site Clinical Solutions, Charlotte, North Carolina
Conditions: Alopecia, Androgenetic